Aptinyx Inc.
aptinyx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2023 10-Q, filed May 18, 2023. Its latest SEC filing is a SC 13G/A from Feb 9, 2024.
10-Q for Q1 FY2023, filed May 18, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops small-molecule drug candidates for disorders of the brain and nervous system, including opioid and alcohol use disorders.
10-K for FY2022, filed Mar 30, 2023We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary…View ↗
Our lead asset, NYX-783, is in Phase 1 clinical development for the treatment of opioid use disorder, or OUD, and in preclinical…View ↗
NYX-783 is a novel, oral, small-molecule NMDAr positive allosteric modulator in development for the treatment of substance use disorders…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2023, filed May 18, 2023
−$21.1MView ↗
- ▲ +6% (Loss)
- vs −$19.8M in Q1 FY2022
-
Dec 21, 2023
Approved a liquidating cash distribution to stockholders
The distribution is $0.0986975 per share and was expected to be paid on or about December 29, 2023.
Sources
8-K, filed Dec 21, 2023
As previously announced, on December 15, 2023, the Board of Directors of Aptinyx Inc. (the “Company”) authorized and approved a liquidating…View ↗
-
Dec 18, 2023
Completed dissolution and began the wind-up
The company filed its certificate of dissolution and began its statutory three-year wind-up period.
Sources
8-K, filed Dec 18, 2023
As previously announced, on June 30, 2023, at a special meeting of stockholders of Aptinyx Inc. (the “Company”), the Company’s stockholders…View ↗
-
Jul 3, 2023
Stockholders approved liquidation and dissolution
Andrew Kidd stepped down as interim chief executive and principal financial officer; Craig Jalbert took over as principal executive and financial officer.
Sources
8-K, filed Jul 3, 2023
On June 30, 2023, Andrew Kidd, stepped down from his position as interim chief executive officer and principal executive officer, principal…View ↗
-
May 11, 2023
Nasdaq notified the company its stock would be delisted
Aptinyx did not plan to request a hearing and expected trading to be suspended at the opening of business on May 19, 2023.
Sources
8-K, filed May 11, 2023
On May 10, 2023, Aptinyx Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock…View ↗
Pipeline focus
The older report described candidate programs for chronic pain, PTSD and Parkinson’s-related cognitive impairment. The latest report centers on opioid and alcohol use disorders after discontinuing the chronic pain, PTSD and cognitive-impairment programs.
10-K for FY2019, filed Mar 30, 2020 10-K for FY2022, filed Mar 30, 2023We are advancing a pipeline of distinct product candidates derived from our NMDAr modulator discovery platform, or the discovery platform.…View ↗
Our lead asset, NYX-783, is in Phase 1 clinical development for the treatment of opioid use disorder, or OUD, and in preclinical…View ↗
In August 2022, we announced that we were discontinuing the development of NYX-2925 after two Phase 2b studies in chronic pain failed to…View ↗
In February 2023, we discontinued the development of NYX-458 in cognitive impairment associated with Parkinson’s disease and dementia with…View ↗
In March 2023, we completed an analysis of the data available to date (as of February 27, 2023) from the first 100 patients enrolled in our…View ↗
NYX-783 is a novel, oral, small-molecule NMDAr positive allosteric modulator in development for the treatment of substance use disorders…View ↗
Commercialization approach
The older report said Aptinyx primarily planned to develop and commercialize candidates independently. The latest report describes possible pharmaceutical partners for some indications and independent commercialization for more specialized indications.
10-K for FY2019, filed Mar 30, 2020 10-K for FY2022, filed Mar 30, 2023Optimize the development and commercial potential of our product candidates. We own the worldwide commercial rights to NYX‑2925, NYX‑783…View ↗
We intend to develop and, if approved by the FDA, to commercialize our product candidates in the United States. We may work in combination…View ↗
Who Did They Compete With?
Competes with Acadia Pharmaceuticals, ATAI Life Sciences, Avanir Pharmaceuticals, Axsome Therapeutics, Biohaven Pharmaceutical Holding, Cerecor, C.H. Boehringer Sohn, Eli Lilly and, Gate Neurosceinces, Genentech, Janssen Pharmaceuticals, Neumora Therapeutics, Novartis International, Relmada Therapeutics, Sage Therapeutics, Alkermes, AstraZeneca, BioXcel Therapeutics, Cerevel Therapeutics Holding, and Indivior
10-K for FY2022, filed Mar 30, 2023A number of pharmaceutical, biotechnology, and specialty pharmaceutical companies are developing therapies targeting NMDArs. Most of the…View ↗
Loading...
